UDG.L

UDG Healthcare Plc
Societe Generale SA - Form 8.3 - UDG Healthcare plc
17th August 2021, 07:11
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8746I
Societe Generale SA
17 August 2021
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

Société Générale S.A.

Company dealt in

UDG Healthcare plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

€0.05 ordinary shares

Date of dealing

16/08/2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

15,708,359

6.23

1,183

0.00

(2) Derivatives (other than options)

0

0.00

12,130,435

4.81

(3) Options and agreements to purchase/sell

0

0.00

0

0.00

Total

*19,566,117

*7.77

12,131,618

4.81

 

* Include the holding of 3,857,758 shares on borrow products

 

               

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit GBP (Note 5)

Purchase

-

-

Sale

-

-

Total Purchases

-

 

Total Sales

-

 

 

Derivatives transactions (other than options transactions)

 

Product name,
e.g. CFD

Nature of transaction
(Note 6)

Number of relevant securities
(Note 7)

Price per unit GBP
(Note 5)

 

 

 

 

 

(b)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.       OTHER INFORMATION

 

Agreements, arrangements, or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            No

 

Date of disclosure

17/08/2021

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEEAXPXFFEFEEA ]]>
TwitterFacebookLinkedIn